PharmImmune is the OncoDesign team that is located within the IDMIT Department of the Jacob Institute (CEA-FAR).
The PharmImmune/OncoDesign partnership with IDMIT allows PharmImmune and IDMIT to benefit from the means, skills and know-how of each:
- Benefit from the facilities and technological means of IDMIT,
- Benefit from the know-how and expertise of PharmImmune,
- Develop joint research and development programs:
- Development of new bio-assays,
-Development of new experimental models, - Contribute/cooperate in the operationality of high-tech platforms:
- Homogenization and standardization of tests,
- Adaptation of the tests to the needs of the clients,
- Accompaniment of the IS0 90012015 standard of management by the quality of IDMIT-FAR laboratories/technology platforms, - Provide a professionalized service to the pharmaceutical manufacturers and institutions developing medicines or diagnostic products: to respond jointly and in a complementary manner to all regulatory phases that precede the first clinical trials,
- Facilitate the establishment of service and/or research delivery contracts,
- Adaption to the constraints of the client: confidentiality, respect of deadlines, regulatory reports.